- Home
- ESLA vs OMIC Comparison
ESLA vs OMIC Comparison
Compare ESLA & OMIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- OMIC
- Stock Information
- Founded
- ESLA 2021
- OMIC 2016
- Country
- ESLA United States
- OMIC United States
- Employees
- ESLA N/A
- OMIC N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- OMIC Medical/Dental Instruments
- Sector
- ESLA Health Care
- OMIC Health Care
- Exchange
- ESLA Nasdaq
- OMIC Nasdaq
- Market Cap
- ESLA 41.6M
- OMIC 49.8M
- IPO Year
- ESLA N/A
- OMIC 2021
- Fundamental
- Price
- ESLA $1.07
- OMIC $19.80
- Analyst Decision
- ESLA
- OMIC Hold
- Analyst Count
- ESLA 0
- OMIC 2
- Target Price
- ESLA N/A
- OMIC $10.75
- AVG Volume (30 Days)
- ESLA 23.1K
- OMIC 21.8K
- Earning Date
- ESLA 02-12-2025
- OMIC 11-12-2024
- Dividend Yield
- ESLA N/A
- OMIC N/A
- EPS Growth
- ESLA N/A
- OMIC N/A
- EPS
- ESLA N/A
- OMIC N/A
- Revenue
- ESLA N/A
- OMIC $2,667,000.00
- Revenue This Year
- ESLA N/A
- OMIC $0.82
- Revenue Next Year
- ESLA N/A
- OMIC $252.64
- P/E Ratio
- ESLA N/A
- OMIC N/A
- Revenue Growth
- ESLA N/A
- OMIC 2.77
- 52 Week Low
- ESLA $0.63
- OMIC $5.34
- 52 Week High
- ESLA $3.23
- OMIC $23.41
- Technical
- Relative Strength Index (RSI)
- ESLA 44.96
- OMIC 50.22
- Support Level
- ESLA $1.02
- OMIC $19.25
- Resistance Level
- ESLA $1.22
- OMIC $20.00
- Average True Range (ATR)
- ESLA 0.17
- OMIC 0.36
- MACD
- ESLA -0.02
- OMIC 0.02
- Stochastic Oscillator
- ESLA 16.67
- OMIC 74.42
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About OMIC Singular Genomics Systems Inc.
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.